DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease
February 18, 2014– DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and the Icahn School of Medicine at Mount Sinai announced today that they entered into a research collaboration agreement to investigate the …
Mount Sinai Genetic Testing Laboratory Launches More Accurate Carrier Screening Test for Spinal Muscular Atrophy
February 11, 2014 – The Icahn School of Medicine at Mount Sinai today announced the launch of a more accurate carrier screening test for spinal muscular atrophy (SMA), one of the most common and severe autosomal recessive disorders. This new test will help prospective …
Repurposing Drugs for Alzheimer’s Disease and Related Dementias Request for Proposals (RFP)
Neurodegenerative diseases represent one of the most difficult classes of diseases for which to develop drugs, yet the need is great with nearly 36 million people currently suffering from Alzheimer’s disease and related dementias worldwide. There are many different pathways that influence …
Single microRNA powers motor activity: Findings have implications for treating severe treatment-refractory epilepsy, says Mount Sinai researcher
December 5, 2013 – New research from the Icahn School of Medicine at Mount Sinai shows that microRNA-128 is one of the strongest regulators of nerve cell excitability and motor activity, and that it does so by adjusting an entire neuronal signaling …
Berg and Icahn School of Medicine at Mount Sinai Announce R&D Partnership for Drug Discovery and Development
October 10, 2013 – Berg, a biopharmaceutical company committed to a data-driven, biological research approach and the Icahn School of Medicine at Mount Sinai announced today a pharmaceutical and diagnostic R&D partnership that will leverage the power of multi-omic biology and data …
Dual Therapeutics, a New Oncology Start-up, is Launched by BioMotiv and the Icahn School of Medicine at Mount Sinai
October 9, 2013 – BioMotiv, a drug development accelerator based in Cleveland, and the Icahn School of Medicine at Mount Sinai, based in New York, are announcing the formation of Dual Therapeutics, a company focused on producing therapeutics for prostate cancer, lung …
Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
September 10, 2013 – Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, has granted an exclusive license to Plexcera Therapeutics, LLC to commercially develop recombinant human acid ceramidase (rhAC) to treat diseases caused by genetic or …
Mount Sinai and Exosome Diagnostics Partner to Accelerate Translation of Body Fluid Molecular Diagnostics to Overcome Limitations of Tissue Biopsy in Areas of Critical Unmet Medical Needs
August 21, 2013 – The Icahn School of Medicine at Mount Sinai and Exosome Diagnostics today announced a collaboration on the research and development of real-time nucleic acid-based body-fluid diagnostics to advance personalized medicine. Exosome will provide technical and development support to Mount Sinai researchers along with early …
Two Mount Sinai Researchers Named “Inventors of the Year” by the New York Intellectual Property Law Association
June 28, 2013 – The New York Intellectual Property Law Association (NYIPLA) has honored two researchers at the Icahn School of Medicine at Mount Sinai with its 2013 Inventor of the Year Award in recognition of their work on Niemann-Pick Disease, or NPD. The …
Mount Sinai Researchers Succeed in Programming Blood Forming Stem Cells
June 14, 2013 – By transferring four genes into mouse fibroblast cells, researchers at the Icahn School of Medicine at Mount Sinai have produced cells that resemble hematopoietic stem cells, which produce millions of new blood cells in the human body every day. These findings …